NCT07018622 2026-03-11
DAPA-ARMOR
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase 2 Recruiting
Clinical Trials
20 trialsNCT07436663 2026-02-27
SGLT2i/DPPi
Tanta University
Phase 4 Not yet recruiting
NCT07310433 2025-12-30
Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer
The University of Hong Kong
Phase 2 Not yet recruiting
NCT05521984 2025-12-08
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
Washington University School of Medicine
Phase 1 Recruiting
NCT07245069 2025-11-24
Alpaca
University Medical Centre Ljubljana
Phase 2 Recruiting
NCT04887935 2025-10-01
Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer
Washington University School of Medicine
Phase 1 Recruiting
NCT06491680 2025-09-22
Cardiotoxicity in Breast Cancer Patients
Helwan University
Phase 4 Recruiting
NCT07070765 2025-07-23
SPRINT
University of Aberdeen
Phase NA Not yet recruiting
NCT07033585 2025-07-11
GD-T2D
Medicine Invention Design, Inc
Phase 2/3 Active not recruiting
NCT05989347 2025-03-19
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy
Yale University
Phase 1 Recruiting
NCT06711185 2024-12-02
DAPA-MYOCANCER
University of Campinas, Brazil
Phase 3 Recruiting
NCT06576375 2024-10-22
Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome
Future University in Egypt
Phase 3 Recruiting
NCT04899349 2024-10-09
EPIK-B4
Novartis
Phase 2 Terminated
NCT06427226 2024-05-23
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity
Tanta University
Phase 2 Not yet recruiting
NCT06405178 2024-05-08
Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome
Beni-Suef University
Phase 3 Not yet recruiting
NCT06341842 2024-04-02
PROTECT
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase 2 Recruiting
NCT04542291 2023-02-14
Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition
Washington University School of Medicine
Phase 1 Completed
NCT04213677 2023-01-12
DEAP
Nanfang Hospital, Southern Medical University
Phase 3 Completed
NCT05025735 2021-10-19
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
Saint Luke's Health System
Phase 2 Unknown
NCT02635386 2021-01-29
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
Woman's
Phase 3 Completed